Loading...
•
Sep 30, 2024
Voyager Therapeutics Q3 2024 Earnings Report
Voyager Therapeutics reported financial results for Q3 2024, showcasing increased collaboration revenue and a reduced net loss compared to the same period in 2023.
Key Takeaways
Voyager Therapeutics reported increased collaboration revenue and a reduced net loss for the third quarter of 2024. The company's cash position remains strong, providing a runway into 2027.
Licensed TRACER™ capsid to Novartis in 5th partnered program, receiving $15 million upfront.
Achieved 3rd development candidate in partnership with Neurocrine, triggering a $3 million milestone payment.
Completed enrollment and dosing in the single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s, with top-line data expected in H1 2025.
Cash, cash equivalents and marketable securities were $345.4 million as of September 30, 2024.
Revenue by Segment
Forward Guidance
Voyager expects its cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...